Breakthrough SaaMD enables smartphones to be used as class-leading stethoscopes that capture, analyze and share cardiovascular and pulmonary sound data ST. JOHN’S, Newfoundland–(BUSINESS WIRE)–Sparrow BioAcoustics today announced it has received clearance from the U.S. Food and Drug Administration to market its software that allows smartphones to be used as medical stethoscopes. […]
Other News
INJECTAFER® Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure
INJECTAFER is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency BASKING RIDGE, N.J. & SHIRLEY, N.Y.–(BUSINESS WIRE)–Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug Administration […]
Shimadzu Medical Systems USA receives an IMV ServiceTrak Award in the General X-ray category
TORRANCE, Calif. , June 5, 2023 /PRNewswire/ — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, receives an IMV ServiceTrak Award in the General X-ray Systems category. In the recent, 2022 ServiceTrak General X-ray series, Shimadzu Medical Systems USA received the highest customer satisfaction rating for “Best System Performance”. IMV produces a series of proprietary […]
NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023
– Met Primary Endpoint with 63.4% Median Reduction in LDL-C (p<0.0001) – – 87.1% of Patients Treated with Combination of Obicetrapib and Ezetimibe Met Guideline-Recommended LDL-C Goal of <55 mg/dL compared to 0% of Patients Treated with Placebo (p<0.05) – – New Data Demonstrate Statistically Significant and Clinically Meaningful Improvements in Additional […]
Microbot Medical Announces $1.5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT) today announced that it has entered into definitive agreements for the purchase and sale of 701,756 shares of the Company’s common stock at a purchase price of $2.1375 per share of common stock in a registered direct […]
Medtronic names Ken Washington new Chief Technology and Innovation Officer
DUBLIN, June 1, 2023 /PRNewswire/ — Medtronic plc (NYSE:MDT) today announced that Ken Washington, Ph.D., has been appointed Medtronic Chief Technology and Innovation Officer. In this newly created role, Dr. Washington will leverage his extensive experience leading technology development and execution across industries including robotics, consumer products, automotive, and space, to accelerate innovation-driven […]
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., June 01, 2023 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted equity awards on June 1, 2023 that were approved by the Compensation Committee of its Board of […]
Microbot Medical Receives a Non-Dilutive Grant from The Israel Innovation Authority Supporting the Development of the Manufacturing Process for its Endovascular Surgical Robotic System
HINGHAM, Mass., June 02, 2023 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic surgical system, announced it has received a grant from the Israel Innovation Authority (“IIA”) in the amount of NIS 1.62 million, which based on a […]
Gradient Denervation Technologies Enrolls Initial Patient in First-In-Human Study of Pulmonary Artery Denervation Technology
Company plans Early Feasibility Study in the US for late 2023 PARIS, FRANCE / ACCESSWIRE / June 1, 2023 / Gradient Denervation Technologies, a Paris-based medical device company developing a minimally-invasive device for treating certain heart failure patients with associated pulmonary hypertension, announced today the successful first patient enrollment in its […]
Amarin Partner EddingPharm Receives Regulatory Approval for Vascepa® (Icosapent Ethyl) in Mainland China
VASCEPA Approved by the National Medical Products Administration (NMPA) as an Adjunct to Diet to Reduce Triglyceride Levels in Adult Patients with Severe Hypertriglyceridemia (≥ 500 mg/dL) — — EddingPharm Now Working Towards Preparing for Commercial Launch of VASCEPA Across Mainland China Expected by Year-End — DUBLIN, Ireland and BRIDGEWATER, […]



